+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 60Years
All Genders
Healthy Volunteers
ID06503510

Evaluating Lebrikizumabs Effect on Pain and Itch Sensitivity in Adults with Atopic Dermatitis and Healthy Volunteers

Led by Aalborg University · Updated on 2025-06-04

20

Participants Needed

3

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Atopic dermatitis is a chronic inflammatory skin condition affecting about 20% of people worldwide, characterized mainly by intense itch and skin pain. Researchers are studying the role of the protein interleukin-13 IL-13 in causing itch by using the drug Lebrikizumab, which blocks IL-13, to better understand how this protein influences itch and pain in both healthy people and those with atopic dermatitis. Participants will receive Lebrikizumab through injections under the skin, starting with two doses of 500 mg at baseline and week 2, followed by 250 mg at week 4. The study uses substances like histamine, cowhage, and BAM8-22 to induce itch and pain for assessment. This experimental treatment aims to modify the IL-13 pathway to observe its effects on itch and pain sensitivity. During the study, participants will have itch and pain measured using computerized scales shortly after itch is induced, along with assessments of blood flow and skin reactions. Various pain and sensitivity thresholds will be tested at baseline. Participants will be monitored closely throughout the study period, which runs until the end of 2026, to evaluate these outcomes and ensure safety.

CONDITIONS

Brief Title

Role of Interleukin-13 Pathways on Pain and Itch Sensitivity

Research Team

S

Silvia Lo Vecchio

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here